CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D)
based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile
of a single agent CKD-581 injection in Combination with Lenalidomide and Dexamethasone in
patients with Previously Treated Multiple Myeloma.